| Bioactivity | BMY-25271 is a histamine H2 receptor antagonist. |
| Target | Histamine H2 receptor |
| In Vivo | BMY-25271 is a histamine H2 receptor antagonist. The dose response curves are parallel and oral ED50 values derived from probit analysis are 0.093, 0.97 and 6.9 mg/kg for BMY-25271, ranitidine and cimetidine, respectively. BMY-25271, therefore, is about 10 and 74 times more potent than ranitidine and cimetidine, respectively. Pretreatment with the highest dose of BMY-25271 does not significantly affect the absorption of aspirin or the formation of its major metabolite, salicylic acid[1]. |
| Name | BMY-25271 |
| CAS | 78441-82-4 |
| Formula | C12H19N5O2S2 |
| Molar Mass | 329.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Cavanagh RL, et al. Prevention of aspirin-induced gastric mucosal injury by histamine H2 receptor antagonists: a crossover endoscopic and intragastric pH study in the dog. J Pharmacol Exp Ther. 1987 Dec;243(3):1179-84. |